Prospective and retrospective studies of vitamin D levels and breast cancer have produced discrepant results. This may be due to variations in serum 25-hydroxyvitamin D (25(OH)D) concentrations over time, including systematic changes after breast cancer diagnosis. We measured total serum 25(OH)D levels in participants from the Sister Study, a US cohort study of sisters of breast cancer patients, who provided samples at baseline (2003)(2004)(2005)(2006)(2007)(2008)(2009)) and 4-10 years later (2013)(2014)(2015). This included 827 women with an intervening breast cancer and 771 women without one. Although 25(OH)D levels were modestly correlated over time (R = 0.42), 25(OH)D concentrations increased in both groups, with larger increases among cases (averaging 31.6 ng/mL at baseline and 43.5 ng/mL at follow-up) than among controls (32.3 ng/mL at baseline, 40.4 ng/mL at follow-up). Consequently, the estimated association between 25(OH)D and breast cancer depended on whether baseline measurements (per 10-ng/mL increase, odds ratio = 0.87, 95% confidence interval: 0.78, 0.98) or measurements from the second blood draw (per 10-ng/mL increase, odds ratio = 1.17, 95% confidence interval: 1.08, 1.26) were used. Concentrations were related to regular use (≥4 times/week) of vitamin D supplements, which became more common over time; increases in regular use were greater in cases (from 56% to 84%) than in controls (from 56% to 77%). Our results do not explain previously observed differences between retrospective and prospective studies, but they do demonstrate how reverse causation and temporal trends in exposure can distort inference. Although many retrospective case-control studies that measured 25(OH)D after the cases had been diagnosed found evidence suggesting that 25(OH)D is inversely associated with breast cancer (5-9), results from prospective cohort studies have been less consistent. In most, prediagnostic 25(OH)D concentrations were either not associated with or only weakly inversely associated with breast cancer (2, 10-25).
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Prospective and retrospective studies of vitamin D levels and breast cancer have produced discrepant results. This may be due to variations in serum 25-hydroxyvitamin D (25(OH)D) concentrations over time, including systematic changes after breast cancer diagnosis. We measured total serum 25(OH)D levels in participants from the Sister Study, a US cohort study of sisters of breast cancer patients, who provided samples at baseline (2003) (2004) (2005) (2006) (2007) (2008) (2009) ) and 4-10 years later (2013) (2014) (2015) . This included 827 women with an intervening breast cancer and 771 women without one. Although 25(OH)D levels were modestly correlated over time (R = 0.42), 25(OH)D concentrations increased in both groups, with larger increases among cases (averaging 31.6 ng/mL at baseline and 43.5 ng/mL at follow-up) than among controls (32.3 ng/mL at baseline, 40.4 ng/mL at follow-up). Consequently, the estimated association between 25(OH)D and breast cancer depended on whether baseline measurements (per 10-ng/mL increase, odds ratio = 0.87, 95% confidence interval: 0.78, 0.98) or measurements from the second blood draw (per 10-ng/mL increase, odds ratio = 1.17, 95% confidence interval: 1.08, 1.26) were used. Concentrations were related to regular use (≥4 times/week) of vitamin D supplements, which became more common over time; increases in regular use were greater in cases (from 56% to 84%) than in controls (from 56% to 77%). Our results do not explain previously observed differences between retrospective and prospective studies, but they do demonstrate how reverse causation and temporal trends in exposure can distort inference. Vitamin D has known anticarcinogenic properties (1), but previous clinical trials and observational studies have not established a clear association between vitamin D and breast cancer risk (2) (3) (4) . Observational studies of the association between breast cancer and levels of the vitamin D biomarker 25-hydroxyvitamin D (25(OH)D) have produced mixed results. Although many retrospective case-control studies that measured 25(OH)D after the cases had been diagnosed found evidence suggesting that 25(OH)D is inversely associated with breast cancer (5-9), results from prospective cohort studies have been less consistent. In most, prediagnostic 25(OH)D concentrations were either not associated with or only weakly inversely associated with breast cancer (2, (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) .
In our recent prospective study of serum 25(OH)D and breast cancer risk (26) , we found that high concentrations of 25(OH)D were associated with decreased risk of breast cancer over the subsequent 5 years. We had restricted the follow-up interval because 25(OH)D levels vary over time (27) (28) (29) and recent exposure could be most relevant to risk, with attenuation of effect estimates over the course of prolonged follow-up periods. We further hypothesized that the protective association observed in retrospective case-control studies could also be due, in part, to reverse causation, with recently diagnosed cases experiencing lifestyle changes or treatment effects that reduced their 25(OH)D concentrations. However, because we only had measurements taken at a single time point prior to cases' diagnoses, we could not estimate effects of either time or breast cancer on 25(OH)D levels.
We undertook this new study to address those remaining gaps. Specifically, we aimed to assess serum 25(OH)D concentrations in samples collected several years after baseline to study changes over time. If changes did occur, we wanted to understand what factors influenced these changes, with particular attention to an intervening breast cancer diagnosis.
METHODS

Description of study participants
Participants were sampled from a prospective cohort study, the Sister Study, which included 50,884 women who had never had breast cancer when they enrolled. To be eligible, women had to have at least 1 sister previously diagnosed with breast cancer, be aged 35-74 years, and live in the United States. During enrollment (2003) (2004) (2005) (2006) (2007) (2008) (2009) ), participants completed a computerassisted telephone interview, providing data on demographic characteristics, reproductive history, personal and familial health histories, and other topics. Trained medical examiners collected biospecimens and took body measurements, and all participants provided written informed consent. The study was approved and overseen by the institutional review boards of the National Institute of Environmental Health Sciences and the Copernicus Group.
Sister Study participants are recontacted annually for updates on their health. More detailed questionnaires are completed every 2-3 years. Women with incident cancer are asked to provide a copy of the pathology report and to authorize release of their medical records. All analyses conducted here were based on data collected through September 2016 (data release 6.0).
We previously assessed baseline 25(OH)D concentrations in 3,386 women for a case-cohort study of incident breast cancer (26) . This included 1,843 women randomly selected from the cohort (including 68 cases) and an additional 1,543 women who had been diagnosed with ductal carcinoma in situ or invasive breast cancer within 5 years of baseline. During 2013-2015, a total of 3,707 women who had provided baseline blood samples (1,838 who had developed breast cancer and 1,869 women who had not) were asked to provide a second blood sample. We successfully collected second samples for 1,144 cases (62%) and 1,214 controls (65%). Of these participants, 1,598 women (827 cases, 771 controls) with baseline 25(OH)D measurements were randomly selected for inclusion in this study of 25(OH)D levels over time.
Assessment of serum 25(OH)D levels
The same protocols were used to collect, store, ship, and analyze baseline and follow-up serum samples for assessment of 25(OH)D concentration (26) . Briefly, blood was collected during in-home examinations and shipped overnight to our laboratory for aliquoting (30) . All samples were stored at −80°C in 0.4-to 0.5-mL straws before being shipped to Heartland Assays LLC (Ames, Iowa). Once there, samples were analyzed for 25(OH)D3, 25(OH)D2, and 3-epi-25(OH)D3 concentrations using liquid chromatography-mass spectrometry with an Agilent 1290 series high-pressure liquid chromatography system (Agilent Technologies, Santa Clara, California) and an Agilent 6460 triple quadrupole liquid chromatography-mass spectrometry system (Agilent Technologies). We summed the concentrations of the 3 metabolites, using that total as our measure of interest. Individual metabolite concentrations below the limit of detection (1.5 ng/mL) were assigned a value of 1.06 ng/mL (1.5/√2). This occurred for 0%, 69%, and 26% of 25(OH)D3, 25(OH)D2, and 3-epi-25(OH)D3 measurements, respectively, at baseline and 0%, 85%, and 21% of 25(OH)D3, 25(OH)D2, and 3-epi-25(OH)D3 measurements, respectively, at follow-up. We adjusted for batch and season of blood draw using randomeffects models and locally weighted scatterplot smoothing (LOESS) regression, respectively, with the LOESS analyses stratified by race/ethnicity (African-American vs. non-African-American) and regular vitamin D supplement use (use ≥4 days/week vs. <4 days/week).
The baseline and second blood samples were analyzed separately, in 2015 and 2017, respectively. For quality control across batches and over time, each batch included 2 samples drawn from pooled sera. One of the pools combined sera from premenopausal women and the other combined sera from postmenopausal women. For the 2015 analysis, we observed interbatch coefficients of variation of 11.0% and 8.5% for the premenopausal and postmenopausal samples, respectively. Precision improved for the 2017 samples, with coefficients of variation of 5.4% and 4.9%, respectively. The quality control samples showed slightly lower values for the 2017 assays versus the 2015 assays (Fisher's combined P value for t tests: P = 0.07).
Statistical analysis
Correlation over time. We first calculated Spearman's rank correlation coefficients (R) and P values to compare withinindividual total 25(OH)D concentrations at the 2 time points. This was done for all samples together and then separately for cases and controls. We also calculated intraclass correlation coefficients (ICCs).
Predictors of changes over time. We next constructed predictive models to assess how within-individual changes in certain factors over time were related to within-individual changes in 25(OH)D concentrations. The covariates considered included an intervening breast cancer diagnosis, time between sample collections, average age across the study period, and changes in the following variables across the 2 times of blood collection: hormonal birth control use, hormone therapy use, physical activity level, body mass index (BMI; weight (kg)/height (m) 2 ), alcohol consumption, history of osteoporosis, menopausal status, vitamin D supplement use, time spent outdoors, smoking status, geographic location, waist circumference, waist:hip ratio, use of protective clothing, and incident bone fractures. We did not adjust for baseline 25(OH)D level, which would have produced bias towards the mean. For caseonly models, we additionally considered disease-related factors, including tumor stage (0/in situ, I, II, or III/IV), tumor type (lobular or ductal), estrogen receptor status, progesterone receptor status, and human epidermal growth factor receptor status, as well as treatment type: chemotherapy (yes/no), Herceptin (Genentech, Inc., South San Francisco, California)/biological agents (yes/no), radiation (yes/no), hormonal treatment (yes/no), and type of surgery (none, mastectomy, or lumpectomy or other breast-conserving surgery). These were entered into a linear regression model in a stepwise fashion (with P value cutpoints of 0.15 to enter and 0.10 to stay).
We also constructed predictive models to better assess changes in 25(OH)D levels over calendar time versus age time. These models were fitted separately for cases and controls and used restricted cubic spline terms for age and year. We used generalized estimating equations to account for repeated measures (2 per individual). To assess age trends, we obtained the predicted 25(OH)D concentration for specified age values (range, 35-85 years) when year was as observed. We repeated this process to evaluate the predicted 25(OH)D concentration for each year (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) , when age was as observed.
Modeling of 25(OH)D levels and breast cancer risk. We next used logistic regression to assess the relationship between different measures of 25(OH)D concentration and breast cancer risk. For the first set of models, we estimated odds ratios and 95% confidence intervals for the association between breast cancer and baseline 25(OH)D concentration, both continuously and categorized into quartiles (820 cases and 764 controls with complete covariate data). We also estimated odds ratios for the relationship between regular use of vitamin D supplements (use of a vitamin D-containing supplement ≥4 times/week) and breast cancer risk. These models were adjusted for the following covariates, as measured at baseline: age at blood draw (years; continuous), race/ethnicity (non-Hispanic white, black, Hispanic, or other), education (high school or less, some college, bachelor's degree, or graduate degree), current use of hormonal birth control (yes/no), current use of hormone therapy (none, estrogen plus progestin, or estrogen alone), physical activity level (≤5.0 hours/week, 5.1-10.0 hours/week, or ≥10.1 hours/week), BMI (<25.0, 25.0-29.9, or ≥30.0), alcohol consumption (never/former drinker, current drinker of <1 drink/day, or current drinker of ≥1 drink/day), history of osteoporosis (yes/no), parity (0, 1, 2, or ≥3 births), menopausal status (premenopausal or postmenopausal), and a BMI × menopausal status interaction term.
In a second set of logistic regression analyses, we used vitamin D measurements based instead on the second blood draw but adjusted for values of the confounders at their baseline levels. This was meant to represent a retrospective case-control study in which exposure is assessed after cases have been diagnosed but participants are asked to recall covariate information from a prior time point. Lastly, we calculated odds ratios and 95% confidence intervals for the association between vitamin D measures at the second blood draw, adjusting for covariates defined as of the time of that visit (as determined by data from follow-up questionnaires; analysis included 822 cases and 765 controls with complete covariate data). Because very few women reported current use of hormonal birth control at the time of the second blood draw, this was omitted from the model. We additionally combined all types of hormone therapy into an ever/never variable.
Sensitivity analyses. In the first of 2 sensitivity analyses, we stratified cases by time between breast cancer diagnosis and second blood draw (<1.0, 1.0-2.9, or ≥3.0 years). Each set of cases was compared with all controls using logistic regression. In a second sensitivity analysis, we addressed possible selection bias by weighting the included participants by their inverse probability of selection (31, 32) , relative to the subset asked to participate in the nested case-control biospecimen study. The weights for these analyses were calculated separately for cases and controls using logistic regression and included baseline levels of the variables specified for the stepwise regression plus disease-related factors for the cases.
RESULTS
The most notable difference between cases and controls (Table 1) was that although 25(OH)D concentrations increased substantially over time in both groups, controls had higher relative 25(OH)D concentrations at baseline (mean = 32.3 ng/mL vs. 31.6 ng/mL in cases; Figure 1A ) but lower concentrations than cases at the second blood draw (40.4 ng/mL in controls vs. 43.5 ng/mL in cases; Figure 1B ) (P = 7 × 10 −9 for the estimated effect of case status on changes over time). The increase over time was consistent with the increasing proportion of women reporting use of a vitamin D-containing supplement at least 4 times per week (56% for both groups at baseline but 77% and 84% for controls and cases, respectively, at the time of the second blood draw).
Waist circumferences increased over time for both groups, with increasing BMI being seen in controls, an increasing proportion of postmenopausal women (especially among cases), and a slight decrease in current smokers in both groups. Other variables, including physical activity, time spent outdoors, and alcohol consumption, were difficult to compare across time because of differences in how the questions were assessed at baseline versus follow-up (see the Web Appendix, Web Figures  1-6 , available at https://academic.oup.com/aje) but were still useful for comparing cases with controls.
The cases were diagnosed at age 60.3 years, on average (Web Table 1 ). Most tumors were estrogen receptor-positive, progesterone receptor-positive, and human epidermal growth factor receptor 2-negative, and 75% were either stage 0 (in situ) or stage I. Eight-two percent of patients underwent either a mastectomy or a lumpectomy, 72% were treated with a hormonal agent such as tamoxifen or Arimidex (AstraZeneca plc, Cambridge, United Kingdom), 65% received radiation, and 36% received chemotherapy.
Correlation over time
Total 25(OH)D concentrations were modestly correlated over time (R = 0.42, P < 0.001; Web Figure 7 ). ICCs for all participants, for cases, and for controls were 0.18, 0.09, and 0.29, respectively. Tables 2-4 . When we modeled the predicted effects of age and calendar time, we observed that both were positively associated with 25(OH)D levels in cases and controls after mutual adjustment (Web Figure 8) . In both instances, the slope for calendar time was steeper than that for age, indicating that the observed changes were primarily behavioral.
Predictors of changes over time
Modeling of 25(OH)D levels and breast cancer risk
Similar to our previous report (26) , total baseline 25(OH)D concentrations were inversely associated with breast cancer risk (per 10-ng/mL increase, odds ratio (OR) = 0.87, CI: 0.78, 0.98; Table 3 ), with some evidence of a threshold effect for levels in the fourth quartile (for fourth quartile (25(OH)D level ≥38.6 ng/mL) vs. first quartile (25(OH)D level ≤25.3 ng/mL), OR = 0.71, 95% CI: 0.52, 0.98). We also observed an inverse association between regular vitamin D supplement use and breast cancer risk (OR = 0.87, 95% CI: 0.70, 1.07). The associations between vitamin D and breast cancer were similar in analyses restricted to women who were postmenopausal at baseline (Web Table 5 ).
In contrast to these findings, when we examined the relationship between breast cancer status and vitamin D measured at the second time point, adjusting for contemporary covariates, we observed strong positive associations. This was true for the analysis of total 25(OH)D measured continuously (OR = 1.17, 95% CI: 1.08, 1.26) or categorized into quartiles, as well as for the assessment of regular supplement use. Results were nearly identical in models adjusted for covariates measured at baseline.
Sensitivity analyses
The association between 25(OH)D concentration at the second blood draw and breast cancer did not measurably depend on time between diagnosis and the second blood draw (Web Table 6 ). The positive association between regular supplement use at the time of the second blood draw and breast cancer was also consistent over time. Of the women who were invited to a Whenever possible, missing data at follow-up (<1% of observations) were filled in on the basis of baseline data. Remaining missing data: baseline waist circumference, 2 cases; baseline waist:hip ratio, 2 controls and 2 cases; race/ethnicity, 1 case; education, 1 case; physical activity at baseline, 1 control and 2 cases; current birth control use at baseline, 2 controls and 2 cases; current hormone therapy use at baseline, 1 control and 2 cases; current hormone therapy use at follow-up, 5 controls and 4 cases; regular use of vitamin D supplements at baseline, 13 controls and 9 cases; regular use of vitamin D supplements at follow-up, 5 controls and 4 cases; time spent outdoors at baseline, 1 control and 2 cases; alcohol consumption at baseline, 2 controls; parity at baseline, 1 control; parity at follow-up, 1 control.
b Values are expressed as mean (standard deviation participate in the nested case-control biospecimen study, those who participated tended to be older, non-Hispanic white, and better educated, tended to have a lower BMI, and were less likely to be smokers (Web Table 7 ). When we used inverse probability of selection weights to control this selection bias, there was little difference in the effect estimates for 25(OH)D (Web Table 8 ) and a slightly stronger effect estimate for regular supplement use (OR = 1.54, 95% CI: 1.18, 2.01).
DISCUSSION
In this study of serum 25(OH)D concentrations over time and their relationship with breast cancer, we found that 25(OH)D levels were modestly correlated over a 4-to 10-year period.
However, concentrations increased considerably between baseline (2003-2009) and the second blood draw (2013-2014), with a larger increase seen in cases than in controls. These increases mirrored increases in participants' self-reported regular use of vitamin D supplements, again with a higher increase being seen in those with an intervening diagnosis of breast cancer.
In accordance with these trends, although baseline 25(OH)D level was associated with a decreased risk of breast cancer, the later 25(OH)D levels were associated with increased risk. These findings do not help to explain the previously observed differences between retrospective and prospective studies of 25(OH)D concentration and breast cancer, in which only retrospective studies tended to show protection. However, they do demonstrate that reverse causation and temporal trends in exposure can hugely bias effect estimates in retrospective studies. (34) . On the basis of our data, it appears that the increase in vitamin D use may be stronger among women diagnosed with breast cancer. Such women are presumably especially motivated to improve their overall health and survival, decrease their risk of recurrence, and manage treatment side effects.
Our correlation results are lower than those of other studies of 25(OH)D concentrations over time. Not surprisingly, the studies with shorter time intervals between samples generally had higher correlations than those with longer time periods. Samples collected 1 year apart had correlations of 0.65-0.80 (28, 35) or ICCs of 0.90 (36) ; those collected 1-3 years apart had ICCs of 0.68-0.96 (24, 36, 37) ; and longer-term studies showed ICCs of 0.50-0.65 (24, 27) or correlation coefficients of 0.42-0.53 (28, 35) . However, those studies preceded the recent rise in the use of vitamin D supplements.
Discontinuation of hormonal birth control was associated with decreased 25(OH)D levels. However, despite the fact that women were aging and going through menopause (including treatment-induced menopause) over the study period, 25(OH)D levels still increased substantially. Given that neither dietary intake nor time spent outdoors was retained in the stepwise prediction models, it seems likely that increased supplement use was the principal driver of 25(OH)D increases in our participants.
Our initial expectation was that women recently diagnosed with breast cancer would have lower 25(OH)D concentrations because of the effects of the disease, its treatment, or behavioral changes following diagnosis. Thus, we were surprised to see positive associations between retrospectively collected 25(OH)D data and breast cancer-even among women who provided their second serum sample within 1 year of diagnosis. It is possible that the second samples were collected too long after diagnosis to capture transient disease-related decreases. After all, the previous case-control studies that showed inverse associations between retrospectively measured 25(OH)D and breast cancer typically enrolled participants within a few months of their diagnosis (5-7, 9). As such, those studies may have done a better job of capturing recent vitamin D exposure, in which case the previous results may reflect our hypothesis that recent vitamin D exposure is most relevant to breast carcinogenesis. That being said, we note that these previous casecontrol studies also predated the recent increases in vitamin D supplement use (33) . Case-control studies may also have suffered from selection bias, with participating controls being more health-conscious and thus more likely to take supplements than the population from which they were drawn.
A limitation of this study is that the assays for the baseline and follow-up 25(OH)D measurements were done at 2 separate times, thereby increasing overall variability. However, we used the same company and analysis approach for both sets of samples and included some of the same pooled control samples with both sets of assays. Though comparisons of the quality control samples did not show statistically significant differences, there was some weak evidence of systematic differences. If there was a true systematic bias between the two sets of tests, the differences are likely to have been small and should have been nondifferential by case status.
Generalizability is also a concern here, as our participants were mostly non-Hispanic white and well-educated, and all had a sister with a history of breast cancer. Such women probably have higher vitamin D intakes than the general population, though their reported supplement use was consistent with the trends seen in NHANES participants of similar age, race, and education. Additionally, because the response rates for the second blood draws were somewhat low (63%), we examined estimated effects for the original selected sample using inverse probability of selection weights. These analyses produced results similar to those reported in the main analysis.
Strengths of this study include the use of liquid chromatography-mass spectrometry to measure 25(OH)D concentrations and detailed and frequent data collection that allowed us to assess exposure and covariate levels across the study period. To our knowledge, this is also the first study to have compared trends for women with and without intervening breast cancer diagnoses. With these data, we were able to compare results obtained from evaluating the 25(OH)Dbreast cancer association prospectively (prediagnosis) with those obtained from evaluating the association retrospectively (postdiagnosis). Though our finding of an apparent positive association between 25(OH)D and breast cancer in the retrospective analysis using samples taken at follow-up was not what we had expected, the increased use of vitamin D supplements over the study period, especially among cases, offers a plausible explanation for the observed effect estimates in this specific case. More generally, this study provides a cautionary tale supporting the need to consider temporal trends in exposure, especially when those exposures may be affected by disease status.
